Keynote 024 Orr. Consistent with results from keynote‐024 overall, first‐line pembrolizumab improved progression‐free survival and overall survival vs chemotherapy with. In the pembrolizumab arm, the orr was comprised of a 24.5% complete response rate, a 41.1% partial response rate, and a 13.9% stable disease rate.
Consistent with results from keynote‐024 overall, first‐line pembrolizumab improved progression‐free survival and overall survival vs chemotherapy with. In the pembrolizumab arm, the orr was comprised of a 24.5% complete response rate, a 41.1% partial response rate, and a 13.9% stable disease rate.